Tyra Biosciences (TYRA) Research & Development (2020 - 2026)
Quarterly Research & Development rose 34.07% to $33.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $111.4 million through Mar 2026, up 26.86% year-over-year, with the annual reading at $102.9 million for FY2025, 28.54% up from the prior year.
Tyra Biosciences filings provide 7 years of Research & Development readings, the most recent being $33.5 million for Q1 2026.
- Research & Development hit $33.5 million in Q1 2026 for Tyra Biosciences, up from $28.2 million in the prior quarter.
- Across five years, Research & Development topped out at $33.5 million in Q1 2026 and bottomed at $9.6 million in Q1 2022.
- Average Research & Development over 5 years is $18.9 million, with a median of $19.3 million recorded in 2023.
- The largest annual shift saw Research & Development soared 174.98% in 2022 before it grew 0.95% in 2023.
- Tyra Biosciences' Research & Development stood at $10.4 million in 2022, then skyrocketed by 98.82% to $20.7 million in 2023, then grew by 7.27% to $22.2 million in 2024, then rose by 27.08% to $28.2 million in 2025, then increased by 18.75% to $33.5 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Research & Development are $33.5 million (Q1 2026), $28.2 million (Q4 2025), and $25.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | 33.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.47 Mn |
| Dec 31, 2025 | 28.19 Mn |
| Sep 30, 2025 | 25.47 Mn |
| Jun 30, 2025 | 24.31 Mn |
| Mar 31, 2025 | 24.96 Mn |
| Dec 31, 2024 | 22.18 Mn |
| Sep 30, 2024 | 22.70 Mn |
| Jun 30, 2024 | 18.00 Mn |
| Mar 31, 2024 | 17.20 Mn |
| Dec 31, 2023 | 20.68 Mn |
| Sep 30, 2023 | 19.27 Mn |
| Jun 30, 2023 | 12.16 Mn |
| Mar 31, 2023 | 10.41 Mn |
| Dec 31, 2022 | 10.40 Mn |
| Sep 30, 2022 | 10.92 Mn |
| Jun 30, 2022 | 12.05 Mn |
| Mar 31, 2022 | 9.65 Mn |
| Dec 31, 2021 | 7.25 Mn |
| Sep 30, 2021 | 5.48 Mn |
| Jun 30, 2021 | 4.38 Mn |
| Mar 31, 2021 | 3.52 Mn |
| Dec 31, 2020 | 2.93 Mn |
| Sep 30, 2020 | 1.86 Mn |